10 research outputs found
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Exploration of the Antiplatelet Activity Profile of Betulinic Acid on Human Platelets
Betulinic acid, a natural pentacyclic triterpene acid, presents a diverse mode of biological actions including antiretroviral, antibacterial, antimalarial, and anti-inflammatory activities. The potency of betulinic acid as an inhibitor of human platelet activation was evaluated, and its antiplatelet profile against in vitro platelet aggregation, induced by several platelet agonists (adenosine diphosphate, thrombin receptor activator peptide-14, and arachidonic acid), was explored. Flow cytometric analysis was performed to examine the effect of betulinic acid on P-selectin membrane expression and PAC-1 binding to activated platelets. Betulinic acid potently inhibits platelet aggregation and also reduced PAC-1 binding and the membrane expression of P-selectin. Principal component analysis was used to screen, on the chemical property space, for potential common pharmacophores of betulinic acid with approved antithrombotic drugs. A common pharmacophore was defined between the NMR-derived structure of betulinic acid and prostacyclin agonists (PGI2), and the importance of its carboxylate group in its antiplatelet activity was determined. The present results indicate that betulinic acid has potential use as an antithrombotic compound and suggest that the mechanism underlying the antiplatelet effects of betulinic acid is similar to that of the PGI2 receptor agonists, a hypothesis that deserves further investigation.Esthir Gkani Foundation (Ioannina, Greece)Esthir Gkani Foundation (Ioannina, Greece)Regional Operational Programme of Thessaly-Mainland Greece-Epirus Research and Technological Development in the Region of Epirus Research Program "New Knowledge"Regional Operational Programme of ThessalyMainland GreeceEpirus Research and Technological Development in the Region of Epirus Research Program New Knowledg
Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type
Exploration of the Antiplatelet Activity Profile of Betulinic Acid on Human Platelets
Betulinic acid, a natural pentacyclic triterpene acid,
presents
a diverse mode of biological actions including antiretroviral, antibacterial,
antimalarial, and anti-inflammatory activities. The potency of betulinic
acid as an inhibitor of human platelet activation was evaluated, and
its antiplatelet profile against in vitro platelet aggregation, induced
by several platelet agonists (adenosine diphosphate, thrombin receptor
activator peptide-14, and arachidonic acid), was explored. Flow cytometric
analysis was performed to examine the effect of betulinic acid on
P-selectin membrane expression and PAC-1 binding to activated platelets.
Betulinic acid potently inhibits platelet aggregation and also reduced
PAC-1 binding and the membrane expression of P-selectin. Principal
component analysis was used to screen, on the chemical property space,
for potential common pharmacophores of betulinic acid with approved
antithrombotic drugs. A common pharmacophore was defined between the
NMR-derived structure of betulinic acid and prostacyclin agonists
(PGI2), and the importance of its carboxylate group in its antiplatelet
activity was determined. The present results indicate that betulinic
acid has potential use as an antithrombotic compound and suggest that
the mechanism underlying the antiplatelet effects of betulinic acid
is similar to that of the PGI2 receptor agonists, a hypothesis that
deserves further investigation
Quantitative and Qualitative Analysis of Regulatory T Cells (Tregs) in B Cell Chronic Lymphocytic Leukemia (B-CLL)
Red Blood Cell Transfusions in Greece: Results of a Survey of Red Blood Cell Use in 2013
Objective: Greece is ranked as the second highest consumer of blood components in Europe. For an effective transfusion system and in order to reduce variability of transfusion practice by implementing evidence-based transfusion guidelines it is necessary to study and monitor blood management strategies. Our study was conducted in order to evaluate the use of red blood cell units (RBC-U) in nationwide scale mapping parameters that contribute to their proper management in Greece.
Materials and Methods: The survey was conducted by the Working Committee of Transfusion Medicine&Apheresis of the Hellenic Society of Hematology from January to December 2013. The collected data included the number, ABO/D blood group, patients’ department, and storage age of RBC-U transfused.
Results: The number of RBC-U evaluated was 103,702 (17.77%) out of 583,457 RBC-U transfused in Greece in 2013. RBC-U transfused by hospital department (mean percentage) was as follows: Surgery 29.34%, Internal Medicine 29.48%, Oncology/Hematology 14.65%, Thalassemia 8.87%, Intensive Care Unit 6.55%, Nephrology 1.78%, Obstetrics/Gynecology 1.46%, Neonatal&Pediatric 0.31%, Private Hospitals 8.57%. RBC-U distribution according to ABO/D blood group was: A: 39.02%, B: 12.41%, AB: 5.16%, O: 43.41%, D+: 87.99%, D-: 12.01%. The majority of RBC-U (62.46%) was transfused in the first 15 days of storage, 25.24% at 16 to 28 days, and 12.28% at 29-42 days.
Conclusion: Despite a high intercenter variability in RBC transfusions, surgical and internal medicine patients were the most common groups of patients transfused with an increasing rate for internal medicine patients. The majority of RBC-U were transfused within the first 15 days of storage, which is possibly the consequence of blood supply insufficiency leading to the direct use of fresh blood. Benchmarking transfusion activity may help to decrease the inappropriate use of blood products, reduce the cost of care, and optimize the use of the voluntary donor’s gift